BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khai NC, Takahashi T, Ushikoshi H, Nagano S, Yuge K, Esaki M, Kawai T, Goto K, Murofushi Y, Fujiwara T. In vivo hepatic HB-EGF gene transduction inhibits Fas-induced liver injury and induces liver regeneration in mice: a comparative study to HGF. J Hepatol. 2006;44:1046-1054. [PMID: 16466829 DOI: 10.1016/j.jhep.2005.10.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Madonna R, Bolli R, Rokosh G, De Caterina R. Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection: . Journal of Cardiovascular Medicine 2013;14:249-53. [DOI: 10.2459/jcm.0b013e3283542017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
2 Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007;27:174-85. [PMID: 17311611 DOI: 10.1111/j.1478-3231.2006.01424.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
3 Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. Int J Mol Sci 2015;17:E30. [PMID: 26729094 DOI: 10.3390/ijms17010030] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 10.9] [Reference Citation Analysis]
4 Fang YL, Chen XG, W T G. Gene delivery in tissue engineering and regenerative medicine. J Biomed Mater Res B Appl Biomater 2015;103:1679-99. [PMID: 25557560 DOI: 10.1002/jbm.b.33354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
5 Matsuda E, Obama Y, Kosai KI. Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene therapy for type 1 diabetes in mice. Life Sci 2021;268:119014. [PMID: 33412216 DOI: 10.1016/j.lfs.2020.119014] [Reference Citation Analysis]
6 Atta HM. Gene therapy for liver regeneration: Experimental studies and prospects for clinical trials. World J Gastroenterol 2010; 16(32): 4019-4030 [PMID: 20731015 DOI: 10.3748/wjg.v16.i32.4019] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Mitsui K, Ide K, Takahashi T, Kosai KI. Viral Vector-Based Innovative Approaches to Directly Abolishing Tumorigenic Pluripotent Stem Cells for Safer Regenerative Medicine. Mol Ther Methods Clin Dev 2017;5:51-8. [PMID: 28480304 DOI: 10.1016/j.omtm.2017.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
8 Chen CL, Mehta VB, Zhang HY, Wu D, Otabor I, Radulescu A, El-Assal ON, Feng J, Chen Y, Besner GE. Intestinal phenotype in mice overexpressing a heparin-binding EGF-like growth factor transgene in enterocytes. Growth Factors 2010;28:82-97. [PMID: 19939201 DOI: 10.3109/08977190903407365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
9 Yasuzaki H, Yoshida S, Hashimoto T, Shibata W, Inamori M, Toya Y, Tamura K, Maeda S, Umemura S. Involvement of the apelin receptor APJ in Fas-induced liver injury. Liver Int 2013;33:118-26. [PMID: 23121371 DOI: 10.1111/liv.12006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
10 Watanabe M, Nishikawaji Y, Kawakami H, Kosai KI. Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy. Viruses 2021;13:2502. [PMID: 34960772 DOI: 10.3390/v13122502] [Reference Citation Analysis]
11 Sakamoto K, Khai NC, Wang Y, Irie R, Takamatsu H, Matsufuji H, Kosai KI. Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms. Int J Mol Med 2016;38:1673-82. [PMID: 27779646 DOI: 10.3892/ijmm.2016.2784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Suzuki H, Toyoda M, Horiguchi N, Kakizaki S, Ohyama T, Takizawa D, Ichikawa T, Sato K, Takagi H, Mori M. Hepatocyte growth factor protects against Fas-mediated liver apoptosis in transgenic mice. Liver International 2009;29:1562-8. [DOI: 10.1111/j.1478-3231.2009.02102.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
13 Chen S, Zheng J, Hao Q, Yang S, Wang J, Chen H, Chen L, Zhou Y, Yu C, Jiao B, Cai Z. p53-insensitive PUMA down-regulation is essential in the early phase of liver regeneration after partial hepatectomy in mice. J Hepatol 2010;52:864-71. [PMID: 20413175 DOI: 10.1016/j.jhep.2009.12.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
14 Sagmeister S, Drucker C, Losert A, Grusch M, Daryabeigi A, Parzefall W, Rohr-Udilova N, Bichler C, Smedsrød B, Kandioler D, Grünberger T, Wrba F, Schulte-Hermann R, Grasl-Kraupp B. HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis. J Hepatol 2008;49:955-64. [PMID: 18929421 DOI: 10.1016/j.jhep.2008.06.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
15 Dao DT, Anez-Bustillos L, Adam RM, Puder M, Bielenberg DR. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Critical Mediator of Tissue Repair and Regeneration. Am J Pathol 2018;188:2446-56. [PMID: 30142332 DOI: 10.1016/j.ajpath.2018.07.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
16 Zhao Y, Difrancesca D, Wang X, Zarnegar R, Michalopoulos GK, Yin XM. Promotion of Fas-mediated apoptosis in Type II cells by high doses of hepatocyte growth factor bypasses the mitochondrial requirement. J Cell Physiol 2007;213:556-63. [PMID: 17620325 DOI: 10.1002/jcp.21136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
17 Kamisasanuki T, Tokushige S, Terasaki H, Khai NC, Wang Y, Sakamoto T, Kosai K. Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res Commun 2011;413:128-35. [PMID: 21875571 DOI: 10.1016/j.bbrc.2011.08.068] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
18 Li W, Lin SD, Long J. Plasma from patients with liver failure inhibits the proliferation of HepG2 cells. Shijie Huaren Xiaohua Zazhi 2012; 20(14): 1204-1209 [DOI: 10.11569/wcjd.v20.i14.1204] [Reference Citation Analysis]
19 Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Avila MA. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel) 2011;3:2444-61. [PMID: 24212818 DOI: 10.3390/cancers3022444] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
20 Jänicke RU, Sohn D, Schulze-osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008;15:959-76. [DOI: 10.1038/cdd.2008.33] [Cited by in Crossref: 137] [Cited by in F6Publishing: 116] [Article Influence: 9.8] [Reference Citation Analysis]
21 Glanemann M, Shi B, El-zidy N, Gaebelein G, Kronbach Z, Neuhaus P, Nussler AK. Subcutaneous administration of epidermal growth factor: A true treatment option in case of postoperative liver failure? International Journal of Surgery 2009;7:200-5. [DOI: 10.1016/j.ijsu.2009.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, Hotchkiss RS, Bavari S. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J Immunol. 2010;184:327-335. [PMID: 20028660 DOI: 10.4049/jimmunol.0901231] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
23 Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol 2021;18:40-55. [PMID: 32764740 DOI: 10.1038/s41575-020-0342-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
24 Wang Y, Asakawa A, Inui A, Kosai K. Leptin gene therapy in the fight against diabetes. Expert Opin Biol Ther 2010;10:1405-14. [PMID: 20690892 DOI: 10.1517/14712598.2010.512286] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Marquès JM, Belza I, Holtmann B, Pennica D, Prieto J, Bustos M. Cardiotrophin-1 is an essential factor in the natural defense of the liver against apoptosis. Hepatology 2007;45:639-48. [PMID: 17326158 DOI: 10.1002/hep.21508] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
26 Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, Sibilia M, Blobel CP, Khokha R. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest. 2010;120:2731-2744. [PMID: 20628198 DOI: 10.1172/jci42686] [Cited by in Crossref: 64] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
27 Herranz-Itúrbide M, López-Luque J, Gonzalez-Sanchez E, Caballero-Díaz D, Crosas-Molist E, Martín-Mur B, Gut M, Esteve-Codina A, Jaquet V, Jiang JX, Török NJ, Fabregat I. NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice. Redox Biol 2021;40:101841. [PMID: 33493901 DOI: 10.1016/j.redox.2020.101841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Khai NC, Sakamoto K, Takamatsu H, Matsufuji H, Kosai K. Recombinant soluble form of heparin-binding epidermal growth factor-like growth factor protein therapy drastically inhibits Fas-mediated fulminant hepatic failure: Implications in clinical application. Hepatol Res 2011;41:594-6. [PMID: 21535334 DOI: 10.1111/j.1872-034X.2011.00805.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]